Status:

COMPLETED

A Study of LY2623091 in Healthy Participants

Lead Sponsor:

Eli Lilly and Company

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The first purpose of this study is to evaluate the effect of itraconazole (and possibly diltiazem) on the amount of LY2623091 in the blood stream and how long the body takes to get rid of it. The sec...

Eligibility Criteria

Inclusion

  • Healthy participants as determined by medical history, physical examination, clinical laboratory tests, and electrocardiograms (ECGs).
  • Have a body mass index (BMI) between 18 and 32.0 kilograms per square meter (kg/m\^2) inclusive, at screening
  • Female participants must be of non-childbearing potential

Exclusion

  • In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Key Trial Info

Start Date :

November 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2015

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT02300259

Start Date

November 1 2014

End Date

April 1 2015

Last Update

June 26 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Covance Clinical Research Inc

Daytona Beach, Florida, United States, 32117

A Study of LY2623091 in Healthy Participants | DecenTrialz